September 30, 2019 / 5:20 AM / 22 days ago

BRIEF-Novartis Announces Positive Results From Phase III Iridium Asthma Study

Sept 30 (Reuters) - Novartis AG:

* NOVARTIS ANNOUNCES POSITIVE RESULTS FROM PHASE III IRIDIUM STUDY OF INHALED COMBINATION QVM149 IN PATIENTS WITH UNCONTROLLED ASTHMA

* ONCE-DAILY QVM149 DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT IN LUNG FUNCTION VERSUS QMF149, MEETING PRIMARY ENDPOINT

* IRIDIUM IS LARGEST STUDY IN PHASE III PLATINUM CLINICAL DEVELOPMENT PROGRAM, WHICH EVALUATES INHALED COMBINATIONS QVM149 AND QMF149

* SUPERIOR IMPROVEMENT IN LUNG FUNCTION WAS ACHIEVED IN ASTHMA PATIENTS WHO WERE UNCONTROLLED ON TREATMENT WITH A LONG-ACTING BETA AGONIST/INHALED CORTICOSTEROID Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below